Rosetta Genomics Expands Management Team With CMO and CSO
Rosetta Genomics (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that E. Robert Wassman, M.D. and Dganit Bar, Ph.D. will join the Company in the newly created positions of Chief Medical Officer and Chief Scientific Officer, respectively, as of October 22, 2012.
"We are delighted to add Drs. Wassman and Bar to our leadership team. Each brings considerable experience and insight that will be invaluable as we grow Rosetta Genomics into a leading molecular diagnostics and personalized medicine company," stated Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.
In addition to a successful career as a medical geneticist, Dr. Wassman has more than 30 years of experience in executive roles at leading genetic testing companies including Genzyme Genetics, Alfigen/The Genetics Institute, Good Start Genetics, and Genetrix, Specialty Laboratories. Prior to joining Rosetta Genomics, Dr. Wassman was Chief Medical Officer, Executive Vice President & Chief Genomics Officer at Generation Health.
Dr. Wassman is widely published with contributions to medical books and articles in peer-reviewed journals and lay publications. He graduated cum laude from Yale University with a B.S. in Biology and earned his M.D. at Albany Medical College. He conducted his internship in pediatrics at New York Hospital-Cornell University Medical Center and was a Fellow in the Medical Genetics-Division of Medical Genetics, Department of Pediatrics at Harbor-UCLA Medical Center. Dr. Wassman served as a Clinical Assistant Professor of Pediatrics at Harbor UCLA Medical Center for many years subsequently.
Dr. Bar joins Rosetta Genomics with 12 years of experience in drug development. Most recently she was Executive Director, Science and Technology at BioLineRx, Ltd. in Jerusalem, where she supervised the company's out-licensing and partnering activities, managed alliances with U.S. partners, and evaluated new and ongoing projects from both business and scientific aspects.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.